Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials

The Antibody Mediated Prevention trials are assessing whether intravenously-administered VRC01 (10 mg/kg or 30 mg/kg vs placebo) can prevent HIV infection. In a modeling exercise, we used two models to predict the overall prevention efficacy (PE) of each VRC01 dose in preventing HIV infection. For t...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Hum Vaccin Immunother
Hoofdauteurs: Huang, Yunda, Karuna, Shelly, Carpp, Lindsay N., Reeves, Daniel, Pegu, Amarendra, Seaton, Kelly, Mayer, Kenneth, Schiffer, Joshua, Mascola, John, Gilbert, Peter B.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Taylor & Francis 2018
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6183277/
https://ncbi.nlm.nih.gov/pubmed/29683765
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1462640
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items